Immunome licenses Zentalis’ ROR1 ADC and platform technology

Jan. 9, 2024

Immunome Inc. and Zentalis Pharmaceuticals Inc. have entered into an exclusive, worldwide license agreement.

Today's news in brief

BioWorld

BioWorld briefs for May 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for May 9, 2025.

US flag, stock market chart, White House

100 days of uncertainty

BioWorld

The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...

AI generated, 3D rendering of protein degradation

AACR 2025: Induced proximity strategy, beyond degraders

BioWorld

Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...

NME Digest: Q1 2025

BioWorld

A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...